Skip to main content

Table 2 Age, sex and residential location comparisons of standard gamble utility scores using the ‘12 month’ and ‘lifetime’ duration early stage throat cancer (n = 1011)

From: Population-based utility scores for HPV infection and oropharyngeal squamous cell carcinoma among Indigenous Australians

 

Mean (95%CI)

Mean (95% CI)

 
 

Health states

Age groups (years)

P-value

18–40 (n = 539)

> 40 (n = 467)

12 month-early stage throat cancer

S1

0.93 (0.90–0.95)

0.89 (0.86–0.90)

0.0319

S2

0.94 (0.92–0.96)

0.88 (0.85–0.91)

0.0022

S3

0.91 (0.89–0.93)

0.92 (0.89–0.94)

0.6276

S4

0.88 (0.85–0.91)

0.87 (0.84–0.91)

0.8666

S5

0.85 (0.82–0.88)

0.89 (0.86–0.92)

0.0682

S6

0.74 (0.70–0.78)

0.76 (0.72–0.80)

0.3715

Lifetime duration-early stage throat cancer

S1

0.92 (0.91–0.94)

0.89 (0.86–0.90)

0.0220

S2

0.94 (0.92–0.96)

0.88 (0.85–0.91)

0.0012

S3

0.91 (0.89–0.93)

0.92 (0.89–0.94)

0.4072

S4

0.88 (0.86–0.91)

0.87 (0.84–0.90)

0.1565

S5

0.85 (0.82–0.87)

0.89 (0.88–0.92)

0.0456

S6

0.78 (0.74–0.81)

0.81 (0.77–0.84)

0.1970

 

Health states

Sex

P-value

Male (n = 340)

Female (n = 671)

12 month-early stage throat cancer

S1

0.92 (0.89–0.95)

0.90 (0.88–0.93)

0.9539

S2

0.89 (0.86–0.92)

0.93 (0.91–0.95)

0.1330

S3

0.90 (0.87–0.94)

0.91 (0.89–0.94)

0.5348

S4

0.86 (0.82–0.90)

0.89 (0.86–0.91)

0.4739

S5

0.86 (0.82–0.90)

0.87 (0.85–0.90)

0.6064

S6

0.70 (0.65–0.73)

0.77 (0.74–0.80)

0.0262

Lifetime duration-early stage

S1

0.91 (0.89–0.94)

0.90 (0.88–0.92)

0.8810

S2

0.89 (0.86–0.92)

0.92 (0.90–0.94)

0.2170

S3

0.91 (0.88–0.94)

0.92 (0.89–0.94)

0.5278

S4

0.86 (0.82–0.90)

0.89 (0.87–0.91)

0.6202

S5

0.86 (0.82–0.90)

0.87 (0.85–0.90)

0.4975

S6

0.76 (0.72–0.81)

0.81 (0.77–0.84)

0.1204

 

Health states

Location

P-value

Metropolitan (n = 376)

Regional (n = 633)

12 month-early stage throat cancer

S1

0.91 (0.89–0.93)

0.91 (0.88–0.94)

0.9706

S2

0.91 (0.89–0.93)

0.92 (0.90–0.95)

0.5519

S3

0.92 (0.90–0.94)

0.90 (0.87–0.93)

0.4017

S4

0.89 (0.87–0.92)

0.86 (0.82–0.89)

0.0659

S5

0.89 (0.87–0.92)

0.82 (0.79–0.86)

0.0005

S6

0.82 (0.79–0.85)

0.63 (0.58–0.68)

< 0.0001

Lifetime duration-early stage

S1

0.91 (0.88–0.93)

0.91 (0.88–0.93)

0.8955

S2

0.91 (0.89–0.93)

0.92 (0.89–0.95)

0.6136

S3

0.92 (0.90–0.94)

0.90 (0.87–0.93)

0.2756

S4

0.89 (0.87–0.92)

0.86 (0.82–0.89)

0.0555

S5

0.89 (0.87–0.92)

0.82 (0.79–0.86)

0.0005

S6

0.87 (0.85–0.90)

0.66 (0.61–0.70)

< 0.0001

  1. Notes: P-value: Wilcoxon rank sum test. S1: screened, cytology normal. S2: HPV vaccination. S3: screened; HPV positive, endoscopy normal. S4: oral warts. S5: high grade cytology with OIN II-III. S6: early stage invasive throat cancer